Press Release
Valitor to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
Berkeley, CA – July 15, 2026 – Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced that chief scientific officer Wesley Jackson, Ph.D., will share a company overview describing Valitor’s platform technology and pipeline in a presentation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026 at 4:00 p.m. ET.
To access the live webcast or subsequent archived recording of the presentation, please visit the Events section of the Valitor website, located after the News section at https://www.valitorbio.com/#events.
About Valitor
Valitor is conquering limitations of established drug targets by leveraging its multivalent biopolymer technology to maximize benefits for patients. The company is initially focused on developing long-acting molecules aimed at capturing several large markets in ophthalmology. Valitor’s lead product is a long-acting inhibitor of VEGF designed to reliably extend the duration of a single dose in humans to six months or more, which would offer a substantial benefit for the majority of patients that require dosing approximately every 8-12 weeks with the current market leaders. Valitor’s proprietary platform technology has been shown in preclinical models to safely enable intravitreal treatment with unprecedented target tissue durability and potency. For more information on the company, please visit its website at https://www.valitorbio.com/ or follow its LinkedIn page.
Investor Contact
Alexandra Santos
asantos@wheelhouselsa.com
Media Contact
Aljanae Reynolds
areynolds@wheelhouselsa.com